1. Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer
- Author
-
Kazuki Takasaki, Takayuki Ichinose, Haruka Nishida, Yuko Miyagawa, Kei Hashimoto, Saya Watanabe, Yuko Takahashi, Mana Hirano, Haruko Hiraike, Yuko Sasajima, and Kazunori Nagasaka
- Subjects
Interval debulking surgery ,Neoadjuvant chemotherapy ,Ovarian cancer ,Peritoneal washing cytology ,Prognosis ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Background Interval debulking surgery (IDS) following neoadjuvant chemotherapy is a treatment option for advanced ovarian cancer. Optimal surgery is required for better survival; however, while peritoneal washing cytology (PWC) has been identified as a prognostic factor, its comprehensive assessment during IDS remains unexplored. Therefore, we aimed to evaluate PWC efficacy during IDS, alongside other factors including residual disease and the modeled cancer antigen 125 (CA-125) ELIMination rate constant K (KELIM), by retrospectively reviewing the medical records of 25 patients with advanced ovarian cancer underwent neoadjuvant chemotherapy and IDS between January 2017 to June 2023. Results Twelve (48.0%) patients were PWC-positive, and the remainder were PWC-negative. PWC was performed at laparotomy during IDS, after which five (41.7%) PWC-positive and four (30.8%) PWC-negative patients received bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, for maintenance treatment. Four (33.3%) PWC-positive and 10 (76.9%) PWC-negative patients received poly adenosine diphosphate (ADP)-ribose polymerase inhibitors. In patients who received bevacizumab and poly ADP-ribose polymerase inhibitors, overall survival and progression-free survival did not significantly differ between those who were PWC-positive and PWC-negative (p = 0.27 and 0.20, respectively). Progression-free survival significantly differed between those with favorable and unfavorable CA-125 KELIM (p = 0.02). Multivariate analysis indicated that optimal surgery and favorable CA-125 KELIM were associated with better progression-free survival (p
- Published
- 2024
- Full Text
- View/download PDF